AU2019346134C1 - Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody - Google Patents
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody Download PDFInfo
- Publication number
- AU2019346134C1 AU2019346134C1 AU2019346134A AU2019346134A AU2019346134C1 AU 2019346134 C1 AU2019346134 C1 AU 2019346134C1 AU 2019346134 A AU2019346134 A AU 2019346134A AU 2019346134 A AU2019346134 A AU 2019346134A AU 2019346134 C1 AU2019346134 C1 AU 2019346134C1
- Authority
- AU
- Australia
- Prior art keywords
- week
- antibody
- subject
- treatment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023201217A AU2023201217A1 (en) | 2018-09-24 | 2023-02-28 | Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody |
| AU2023100041A AU2023100041B4 (en) | 2018-09-24 | 2023-05-18 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2023100042A AU2023100042B9 (en) | 2018-09-24 | 2023-05-18 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100006A AU2024100006C4 (en) | 2018-09-24 | 2024-02-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100007A AU2024100007C4 (en) | 2018-09-24 | 2024-02-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100016A AU2024100016C4 (en) | 2018-09-24 | 2024-03-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100017A AU2024100017A4 (en) | 2018-09-24 | 2024-03-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100046A AU2024100046B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100045A AU2024100045B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100044A AU2024100044B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735501P | 2018-09-24 | 2018-09-24 | |
| US62/735,501 | 2018-09-24 | ||
| US201862769818P | 2018-11-20 | 2018-11-20 | |
| US62/769,818 | 2018-11-20 | ||
| US201962895774P | 2019-09-04 | 2019-09-04 | |
| US62/895,774 | 2019-09-04 | ||
| PCT/IB2019/058098 WO2020065532A1 (en) | 2018-09-24 | 2019-09-24 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023201217A Division AU2023201217A1 (en) | 2018-09-24 | 2023-02-28 | Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2019346134A1 AU2019346134A1 (en) | 2021-04-01 |
| AU2019346134B2 AU2019346134B2 (en) | 2023-01-12 |
| AU2019346134C1 true AU2019346134C1 (en) | 2024-06-20 |
Family
ID=69885324
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019346134A Ceased AU2019346134C1 (en) | 2018-09-24 | 2019-09-24 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2023201217A Pending AU2023201217A1 (en) | 2018-09-24 | 2023-02-28 | Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody |
| AU2023100042A Revoked AU2023100042B9 (en) | 2018-09-24 | 2023-05-18 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2023100041A Revoked AU2023100041B4 (en) | 2018-09-24 | 2023-05-18 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100007A Revoked AU2024100007C4 (en) | 2018-09-24 | 2024-02-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100006A Revoked AU2024100006C4 (en) | 2018-09-24 | 2024-02-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100016A Revoked AU2024100016C4 (en) | 2018-09-24 | 2024-03-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100017A Ceased AU2024100017A4 (en) | 2018-09-24 | 2024-03-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100044A Revoked AU2024100044B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100046A Revoked AU2024100046B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100045A Revoked AU2024100045B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
Family Applications After (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023201217A Pending AU2023201217A1 (en) | 2018-09-24 | 2023-02-28 | Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody |
| AU2023100042A Revoked AU2023100042B9 (en) | 2018-09-24 | 2023-05-18 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2023100041A Revoked AU2023100041B4 (en) | 2018-09-24 | 2023-05-18 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100007A Revoked AU2024100007C4 (en) | 2018-09-24 | 2024-02-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100006A Revoked AU2024100006C4 (en) | 2018-09-24 | 2024-02-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100016A Revoked AU2024100016C4 (en) | 2018-09-24 | 2024-03-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100017A Ceased AU2024100017A4 (en) | 2018-09-24 | 2024-03-21 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100044A Revoked AU2024100044B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100046A Revoked AU2024100046B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
| AU2024100045A Revoked AU2024100045B4 (en) | 2018-09-24 | 2024-11-29 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10961307B2 (https=) |
| EP (1) | EP3883606B9 (https=) |
| JP (4) | JP7359845B2 (https=) |
| KR (2) | KR20210064315A (https=) |
| CN (2) | CN113164596A (https=) |
| AU (11) | AU2019346134C1 (https=) |
| BR (1) | BR112021005467A2 (https=) |
| CA (2) | CA3160103A1 (https=) |
| CZ (1) | CZ38255U1 (https=) |
| DE (1) | DE202019006083U1 (https=) |
| DK (3) | DK3883606T5 (https=) |
| ES (1) | ES2959463T3 (https=) |
| FI (2) | FI3883606T3 (https=) |
| HR (1) | HRP20230886T1 (https=) |
| HU (1) | HUE063462T2 (https=) |
| IL (2) | IL326284A (https=) |
| LT (1) | LT3883606T (https=) |
| MD (1) | MD3883606T3 (https=) |
| MX (1) | MX2021003411A (https=) |
| PL (1) | PL3883606T3 (https=) |
| PT (1) | PT3883606T (https=) |
| RS (1) | RS64552B9 (https=) |
| SI (1) | SI3883606T1 (https=) |
| SM (1) | SMT202300262T1 (https=) |
| WO (1) | WO2020065532A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005467A2 (pt) | 2018-09-24 | 2021-06-22 | Janssen Biotech, Inc. | método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
| WO2020234834A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| CN114555120A (zh) * | 2019-10-18 | 2022-05-27 | 詹森生物科技公司 | 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法 |
| EP4146273A4 (en) * | 2020-05-05 | 2024-07-31 | Janssen Biotech, Inc. | METHODS OF TREATING CROHN'S DISEASE USING A SPECIFIC ANTI-IL23 ANTIBODY |
| KR20230023663A (ko) | 2020-05-21 | 2023-02-17 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법 |
| EP4178616A4 (en) * | 2020-07-13 | 2024-07-24 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY |
| CA3190230A1 (en) * | 2020-07-30 | 2022-02-03 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
| US20220102008A1 (en) * | 2020-09-30 | 2022-03-31 | Genentech, Inc. | Methods and systems for placebo response modeling |
| TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| EP4376888A4 (en) * | 2021-07-26 | 2025-07-02 | Avalo Therapeutics Inc | METHODS OF TREATING ULCERATIVE COLITIS WITH ANTI-LIGHT ANTIBODIES |
| WO2023056417A1 (en) * | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| WO2025062347A1 (en) * | 2023-09-21 | 2025-03-27 | Janssen Pharmaceutica Nv | Interleukin-23 receptor antagonist for use in the treatment of ulcerative colitis |
| CA3258952A1 (en) * | 2024-06-27 | 2026-03-01 | Janssen Biotech, Inc. | Methods of treating ulcerative colitis with anti-il23 specific antibody |
| WO2026058045A1 (en) | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| DE3852304T3 (de) | 1987-03-02 | 1999-07-01 | Enzon Labs Inc., Piscataway, N.J. | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
| DE68926882T2 (de) | 1988-01-11 | 1997-02-13 | Xoma Corp | Plasmidvektor mit pectatlyase-signalsequenz |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| CA2441636A1 (en) | 1988-11-10 | 1990-05-10 | The Wistar Institute Of Anatomy And Biology | Natural killer stimulatory factor |
| US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
| US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
| DK0494955T3 (da) | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
| ATE366311T1 (de) | 1989-12-22 | 2007-07-15 | Hoffmann La Roche | Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür |
| US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP3306063B2 (ja) | 1990-08-24 | 2002-07-24 | イグジス， インコーポレイテッド | ランダムコドンを有するオリゴヌクレオチドを合成する方法 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| EP0563296B1 (en) | 1990-12-20 | 1999-03-17 | Ixsys, Inc. | Optimization of binding proteins |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
| US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| AU6132994A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| DE4315127A1 (de) | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| WO1995029239A2 (en) | 1994-04-22 | 1995-11-02 | Corixa Corporation | Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| DE19624387C2 (de) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Kaltstartvorrichtung |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| AU6150498A (en) | 1997-02-07 | 1998-08-26 | Wistar Institute, The | Methods and compositions for the inhibition of interleukin-12 production |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| CN1169520C (zh) | 1997-09-29 | 2004-10-06 | 耐科塔医药公司 | 多孔微粒及其使用方法 |
| WO1999037682A2 (en) | 1998-01-23 | 1999-07-29 | F.Hoffmann-La Roche Ag | Antibodies against human il-12 |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| JP3579355B2 (ja) | 1998-12-09 | 2004-10-20 | プロテイン デザイン ラブス インコーポレイティド | ヒトの乾癬を予防及び治療するための乾癬モデル動物 |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| SI2168984T1 (sl) | 1999-03-25 | 2012-12-31 | Abbott Gmbh & Co. Kg | Človeška protitelesa za vezavo IL-12 in postopki izdelave |
| AU7127600A (en) | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
| SE520605C2 (sv) | 2001-06-29 | 2003-07-29 | Flir Systems Ab | Optiskt system innefattande en detektor och en bländare med decentreringsfunktion |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| EP1623011B1 (en) | 2003-05-09 | 2013-01-02 | Janssen Biotech, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
| CN103145839A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| EP2205276A4 (en) | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
| AU2009246053B2 (en) | 2008-05-14 | 2014-07-24 | Agriculture Victoria Services Pty Ltd. | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
| US9118980B2 (en) | 2009-02-17 | 2015-08-25 | Indian Institute of Science (IISc) | Transmit power scaling method and system to detect occurrences using geographically distributed sensors |
| AU2011213609B2 (en) | 2010-02-08 | 2016-11-03 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
| CN103517921B (zh) * | 2010-12-21 | 2017-07-18 | Abbvie 公司 | IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途 |
| JP5412692B2 (ja) | 2011-10-04 | 2014-02-12 | 株式会社モルフォ | 画像処理装置、画像処理方法、画像処理プログラム及び記録媒体 |
| KR101340168B1 (ko) | 2012-05-14 | 2013-12-10 | 현대모비스 주식회사 | 스테이터 권선 코일의 비용접 결선방법 및 이를 적용한 회전모터 |
| US9619256B1 (en) | 2012-06-27 | 2017-04-11 | EMC IP Holding Company LLC | Multi site and multi tenancy |
| US9205258B2 (en) | 2013-11-04 | 2015-12-08 | ElectroCore, LLC | Nerve stimulator system |
| JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| AU2016379157A1 (en) | 2015-12-22 | 2018-06-21 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| WO2018112232A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
| BR112021005467A2 (pt) | 2018-09-24 | 2021-06-22 | Janssen Biotech, Inc. | método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
-
2019
- 2019-09-24 BR BR112021005467-7A patent/BR112021005467A2/pt not_active Application Discontinuation
- 2019-09-24 LT LTEPPCT/IB2019/058098T patent/LT3883606T/lt unknown
- 2019-09-24 SI SI201930606T patent/SI3883606T1/sl unknown
- 2019-09-24 IL IL326284A patent/IL326284A/en unknown
- 2019-09-24 RS RS20230705A patent/RS64552B9/sr unknown
- 2019-09-24 JP JP2021515167A patent/JP7359845B2/ja active Active
- 2019-09-24 ES ES19867085T patent/ES2959463T3/es active Active
- 2019-09-24 PL PL19867085.3T patent/PL3883606T3/pl unknown
- 2019-09-24 SM SM20230262T patent/SMT202300262T1/it unknown
- 2019-09-24 CA CA3160103A patent/CA3160103A1/en active Pending
- 2019-09-24 EP EP19867085.3A patent/EP3883606B9/en active Active
- 2019-09-24 PT PT198670853T patent/PT3883606T/pt unknown
- 2019-09-24 DK DK19867085.3T patent/DK3883606T5/da active
- 2019-09-24 FI FIEP19867085.3T patent/FI3883606T3/fi active
- 2019-09-24 FI FIU20230063U patent/FI13575Y1/fi active IP Right Grant
- 2019-09-24 MD MDE20210930T patent/MD3883606T3/ro unknown
- 2019-09-24 CN CN201980077285.XA patent/CN113164596A/zh active Pending
- 2019-09-24 KR KR1020217012128A patent/KR20210064315A/ko not_active Ceased
- 2019-09-24 AU AU2019346134A patent/AU2019346134C1/en not_active Ceased
- 2019-09-24 HU HUE19867085A patent/HUE063462T2/hu unknown
- 2019-09-24 DE DE202019006083.9U patent/DE202019006083U1/de active Active
- 2019-09-24 CA CA3113837A patent/CA3113837C/en active Active
- 2019-09-24 WO PCT/IB2019/058098 patent/WO2020065532A1/en not_active Ceased
- 2019-09-24 CN CN202510663248.4A patent/CN120514845A/zh active Pending
- 2019-09-24 KR KR1020237034949A patent/KR20230148273A/ko active Pending
- 2019-09-24 US US16/580,509 patent/US10961307B2/en active Active
- 2019-09-24 CZ CZ2023-41221U patent/CZ38255U1/cs active Protection Beyond IP Right Term
- 2019-09-24 MX MX2021003411A patent/MX2021003411A/es unknown
- 2019-09-24 HR HRP20230886TT patent/HRP20230886T1/hr unknown
-
2021
- 2021-02-11 US US17/174,201 patent/US20210171622A1/en not_active Abandoned
- 2021-03-18 IL IL281642A patent/IL281642B1/en unknown
-
2022
- 2022-12-22 JP JP2022205509A patent/JP7481423B2/ja active Active
-
2023
- 2023-02-28 AU AU2023201217A patent/AU2023201217A1/en active Pending
- 2023-05-18 AU AU2023100042A patent/AU2023100042B9/en not_active Revoked
- 2023-05-18 AU AU2023100041A patent/AU2023100041B4/en not_active Revoked
- 2023-07-11 DK DKBA202300038U patent/DK202300038Y9/da active IP Right Grant
- 2023-08-17 JP JP2023133026A patent/JP2023162273A/ja active Pending
- 2023-10-24 US US18/383,310 patent/US20240182557A1/en active Pending
-
2024
- 2024-02-21 AU AU2024100007A patent/AU2024100007C4/en not_active Revoked
- 2024-02-21 AU AU2024100006A patent/AU2024100006C4/en not_active Revoked
- 2024-03-21 AU AU2024100016A patent/AU2024100016C4/en not_active Revoked
- 2024-03-21 AU AU2024100017A patent/AU2024100017A4/en not_active Ceased
- 2024-04-18 DK DKBA202400026U patent/DK202400026Y3/da active IP Right Grant
- 2024-11-29 AU AU2024100044A patent/AU2024100044B4/en not_active Revoked
- 2024-11-29 AU AU2024100046A patent/AU2024100046B4/en not_active Revoked
- 2024-11-29 AU AU2024100045A patent/AU2024100045B4/en not_active Revoked
-
2025
- 2025-02-13 JP JP2025021912A patent/JP2025081433A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023100042B4 (en) | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody | |
| CA3170677A1 (en) | Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody | |
| US20240294625A1 (en) | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | |
| EA051461B1 (ru) | Безопасный и эффективный способ лечения язвенного колита с помощью антител к il-12/il-23 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CB | Opposition filed |
Opponent name: SAMSUNG BIOEPIS AU PTY LTD |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JAN 2024 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 29 JAN 2024 |
|
| ON | Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing) |
Free format text: (2025) APO 32: DECISION: THE OPPOSITION IS SUCCESSFUL ON THE GROUNDS OF NOVELTY AND INVENTIVE STEP. ALL THE CLAIMS OF THE OPPOSED APPLICATION LACK NOVELTY IN VIEW OF THE CITED PRIOR ART. ALL THE CLAIMS OF THE OPPOSED APPLICATION LACK INVENTIVE STEP IN LIGHT OF CITED PRIOR ART CONSIDERED TOGETHER WITH CGK. THE OPPONENT HAS NOT ESTABLISHED THAT ANY OF THE CLAIMS LACK SUPPORT FROM SUBJECT MATTER DISCLOSED IN THE OPPOSED APPLICATION. JANSSEN BIOTECH, INC. IS GIVEN TWO MONTHS FROM THE DATE OF THIS DECISION TO PROPOSE AMENDMENTS TO OVERCOME THE DEFICIENCIES IN THE CLAIMS. COSTS ACCORDING TO SCHEDULE 8 ARE AWARDED AGAINST JANSSEN BIOTECH, INC.. Opponent name: SAMSUNG BIOEPIS AU PTY LTD Effective date: 20251003 |
|
| MK16 | Application refused |